Patent US4152448A successfully refreshed from Google Patents.
US4152448A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method and composition for the treatment of a condition of the gastro intestinal tract
Assignee: Fisons Ltd
•
Filing: 1976-12-29
•
Granted: 1979-05-01
•
Expires: 1996-12-29
Abstract
Abstract There is described a method of treatment of conditions of the gastro intestinal tract, in which conditions allergy or immune reactions play a contributory part, which method comprises per os administration of a compound of the formula I ##STR1## and therapeutically acceptable salts, esters and amides thereof, wherein X is a polymethylene chain containing 3 to 7 carbon atoms inclusive, which chain may be substituted by an --OH group, (as active ingredient), to a patient having such a condition.
Inventors
- 👤 George Wardell
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 02:18
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/335; A61K31/35
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
133 words
A method of treatment of a condition of the gastro-intestinal tract selected from the group consisting of Crohn's disease, atrophic gastritis, ulcerative colites, proctitis, coeliac disease, regional ileitis, peptic ulceration, irritable bowel syndrome and gastro-intestinal bleeding induced by the administration of an anti-inflammatory, which method comprises per os administration of a daily dosage of from 20 to 4,000 mg. of a member selected from the group consisting of a compound of the formula ##STR3## a therapeutically acceptable salt, an alkyl C 1 to 10 ester, a mono-alkyl C 1 to 10 amide, a di-alkyl C 1 to 10 amide and an unsubstituted amide thereof, wherein X is a polymethylene chain containing 3 to 7 carbon atoms inclusive, which chain may be substituted by an --OH group, to a patient having such a condition.
Claim 2
Independent Claim
133 words
A method of treatment of a condition of the gastro-intestinal tract selected from the group consisting of Crohn's disease, atrophic gastritis, ulcerative colites, proctitis, coeliac disease, regional ileitis, peptic ulceration, irritable bowel syndrome and gastro-intestinal bleeding induced by the administration of an anti-inflammatory, which method comprises per os administration of a daily dosage of from 20 to 4,000 mg. of a member selected from the group consisting of a compound of the formula ##STR3## a therapeutically acceptable salt, an alkyl C 1 to 10 ester, a mono-alkyl C 1 to 10 amide, a di-alkyl C 1 to 10 amide and an unsubstituted amide thereof, wherein X is a polymethylene chain containing 3 to 7 carbon atoms inclusive, which chain may be substituted by an --OH group, to a patient having such a condition.
Claim 3
Dependent Claim
17 words
A method according to claim 1 wherein the compound is 1,3-bis(2-carboxy-chromon-5-yloxy)-2-hydroxypropane or a pharmaceutically acceptable salt thereof.
Claim 4
Dependent Claim
17 words
A method according to claim 1 wherein the compound is 1,3-bis(2-carboxy-chromon-7-yloxy)-2-hydroxypropane or a pharmaceutically acceptable salt thereof.
Claim 5
Dependent Claim
21 words
A method according to claim 1 wherein the pharmaceutically acceptable salt is an ammonium, alkali metal or alkaline earth metal salt.
Claim 6
Dependent Claim
22 words
A method according to claim 1, wherein the patient receives unit dosages of from 20 to 1000 mg. of the active ingredient.
Claim 7
Dependent Claim
19 words
A method according to claim 5 wherein the unit doses are from 100 to 750 mg. of active ingredient.
Claim 8
Dependent Claim
19 words
A method according to claim 5, wherein the unit doses are from 200 to 500 mg. of active ingredient.
Claim 9
Dependent Claim
26 words
A method according to claim 1 in which the patient receives from 20 to 250 mg. of the active ingredient 2 to 4 times a day.
Claim 10
Dependent Claim
13 words
A method according to claim 1 wherein the condition treated is Crohn's disease.
Claim 11
Dependent Claim
13 words
A method according to claim 1 wherein the condition treated is atrophic gastritis.
Claim 12
Dependent Claim
13 words
A method according to claim 1 wherein the condition treated is ulcerative colitis.
Claim 13
Dependent Claim
12 words
A method according to claim 1 wherein the condition treated is proctitis.
Claim 14
Dependent Claim
13 words
A method according to claim 1 wherein the condition treated is coeliac disease.
Claim 15
Dependent Claim
13 words
A method according to claim 1 wherein the condition treated is regional ileitis.
Claim 16
Dependent Claim
13 words
A method according to claim 1 wherein the condition treated is peptic ulceration.
Claim 17
Dependent Claim
14 words
A method according to claim 1 wherein the condition treated is irritable bowel syndrome.
Claim 18
Dependent Claim
20 words
A method according to claim 1 wherein the condition treated is gastrointestinal bleeding induced by the administration of an anti-inflammatory.
Claim 19
Independent Claim
127 words
A method for the treatment of a condition of the gastro-intestinal tract selected from the group consisting of Crohn's disease, ulcerative colitis, proctitis, irritable bowel syndrome and gastro-intestinal bleeding induced by the administration of an anti-inflammatory, which method comprises administering to the gastro-intestinal tract of a patient suffering from said condition a daily dosage of from 20 to 4,000 mg. of a member selected from the group consisting of a compound of the formula ##STR4## a therapeutically acceptable salt, an alkyl C 1 to 10 ester, a mono-alkyl C 1 to 10 amide, a di-alkyl C 1 to 10 amide and an unsubstituted amide thereof, wherein X is a polymethylene chain containing 3 to 7 carbon atoms inclusive, which chain may be substituted by an --OH group.
Claim 20
Independent Claim
127 words
A method for the treatment of a condition of the gastro-intestinal tract selected from the group consisting of Crohn's disease, ulcerative colitis, proctitis, irritable bowel syndrome and gastro-intestinal bleeding induced by the administration of an anti-inflammatory, which method comprises administering to the gastro-intestinal tract of a patient suffering from said condition a daily dosage of from 20 to 4,000 mg. of a member selected from the group consisting of a compound of the formula ##STR4## a therapeutically acceptable salt, an alkyl C 1 to 10 ester, a mono-alkyl C 1 to 10 amide, a di-alkyl C 1 to 10 amide and an unsubstituted amide thereof, wherein X is a polymethylene chain containing 3 to 7 carbon atoms inclusive, which chain may be substituted by an --OH group.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1982-04-30 | 1982-10-30 | 1983-05-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1986-04-30 | 1986-10-30 | 1987-05-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1990-04-30 | 1990-10-30 | 1991-05-01 | $7700.00 | Window Closed / Lapsed |